Reteplase is a recombinant tissue plasminogen activator (rtPA) used primarily as a thrombolytic agent in the treatment of acute myocardial infarction. It is a modified form of the natural enzyme plasminogen activator, designed to facilitate the breakdown of blood clots by converting plasminogen to plasmin. Reteplase is characterized by its rapid onset of action and relatively short half-life, which allows for effective clot dissolution when administered promptly. The substance is typically provided as a lyophilized powder for reconstitution before intravenous administration. Its mechanism of action involves binding to fibrin in the thrombus, enhancing the conversion of plasminogen to plasmin, thereby promoting fibrinolysis. Reteplase is generally well-tolerated, but like all thrombolytics, it carries risks of bleeding complications. Its use is contraindicated in certain conditions, such as active bleeding or recent surgery. Overall, Reteplase represents a critical therapeutic option in emergency medicine for managing acute coronary events.

Reteplase

133652-38-7: Reteplase is a recombinant tissue plasminogen activator (rtPA) used primarily as a thrombolytic agent in the treatment of acute myocardial infarction. It is a modified form of the natural enzyme plasminogen activator, designed to facilitate the breakdown of blood clots by converting plasminogen to plasmin. Reteplase is characterized by its rapid onset of action and relatively short half-life, which allows for effective clot dissolution when administered promptly. The substance is typically provided as a lyophilized powder for reconstitution before intravenous administration. Its mechanism of action involves binding to fibrin in the thrombus, enhancing the conversion of plasminogen to plasmin, thereby promoting fibrinolysis. Reteplase is generally well-tolerated, but like all thrombolytics, it carries risks of bleeding complications. Its use is contraindicated in certain conditions, such as active bleeding or recent surgery. Overall, Reteplase represents a critical therapeutic option in emergency medicine for managing acute coronary events.

Reteplase, a recombinant plasminogen activator from t-PA's domains, is made via DNA tech in E. coli.

CAS 133652-38-7

Reteplase

Reteplase

Ref: TM-T64287